Tuesday, September 25, 2018
Skip to main page content U.S. Food and Drug Administration Search FDA Submit search Popular Content Press Announcements FDA Statement Remarks from Anna Abram as prepared for delivery to the 2018 Intergovermental Meeting on Drug Compounding
morning and welcome. I am Anna Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis here at the Food and Drug Administration.
I would like to thank you all for traveling from near and far to be with us today to participate in our seventh intergovernmental meeting on drug compounding. Wherever you hail from, and whether this is your first or seventh meeting, we’re glad to have you join us to continue our ongoing dialogue about ways to reduce the risks associated with compounded drug products and improve collaboration between FDA and the states. We greatly value our work with you, and we feel strongly that our partnerships with you are critical to maintaining robust oversight of compounders to protect the public health.
Politico-21 hours ago
The branded drug lobby also is not anticipated to succeed in using the opioid bill to .... Compounded medicine blamed for serious vision problems — At least 68 ...
Reuters-13 hours ago
A federal judge on Monday ruled that two pharmacists accused of helping fill fake prescriptions while working at a Massachusetts compounding pharmacy linked .